SCHEMBL4676053

SCHEMBL4676053

O=C(C=C(O)c1nc[nH]n1)c1sccc1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.41
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP3A4 P08684 2/20 0.37
TSHR P16473 1/20 0.37
ALDH1A1 P00352 4/20 0.33
POLB P06746 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 3/20 0.31
TP53 P04637 1/20 0.31
HTT P42858 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
EDNRB P24530 1/20 0.31
EDNRA P25101 1/20 0.31
ACHE P22303 1/20 0.31
MAPK1 P28482 1/20 0.31
ACLY P53396 1/20 0.31
AKR1B1 P15121 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673470 0.90 NPSR1 (0.52) NPSR1TSHRALDH1A1POLBKDM4E
SCHEMBL4671731 0.90 NPSR1 (0.41) NPSR1MEN1KMT2AALDH1A1LMNA
SCHEMBL4673071 0.83 ALDH1A1 (0.33) NPSR1MEN1KMT2AALDH1A1POLB
SCHEMBL4675879 0.83 NPSR1 (0.41) NPSR1MEN1KMT2ACYP3A4TSHR
SCHEMBL4676012 0.81 MAPT (0.41) MEN1KMT2ACYP3A4ALDH1A1POLB
SCHEMBL4671593 0.81 AKR1B1 (0.34) NPSR1MEN1KMT2ACYP3A4ALDH1A1
SCHEMBL4680017 0.79 ALDH1A1 (0.33) MEN1KMT2ACYP3A4ALDH1A1LMNA
SCHEMBL4672361 0.79 ALDH1A1 (0.34) MEN1KMT2ACYP3A4ALDH1A1POLB
SCHEMBL4673977 0.79 POLB (0.31) MEN1KMT2ACYP3A4ALDH1A1POLB
SCHEMBL4672762 0.78 NPC1 (0.31) CYP3A4ALDH1A1MAPTMAPK1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPSR1 937/4885MEN1 4663/4885KMT2A 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.